Clinical trials: Change in Bone Mineral Density
Osteoporosis
Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
The objective is to show superior efficacy of PTH (1-84) over risedronate in treating osteoporotic women for 12 months after having previously been treated with PTH (1-84) for 12 months followed by 12 months treatment with…
- Trial name
- PEAK (NCT00365456)
- Testing
- Parathyroid Hormone (PTH), Risedronate
- Where
- Denmark
- Volunteers
- 407 people
- Sponsor
- Takeda
Contraception, Change in Bone Mineral Density
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
This study will be in two parts, Part A and Part B. The primary objective of Part A is to evaluate the contraceptive efficacy of LPRI-CF113.
- Trial name
- NCT05461573
- Testing
- Drospirenone
- Where
- 47 sites in United States, Canada
- Volunteers
- 1,542 people, healthy volunteers welcome
- Sponsor
- Insud Pharma
Osteoporosis
CR9112792, a Follow-up of Study CR9108963
The purpose of this study is to determine whether bone mineral density has increased in a subgroup of postmenopausal osteoporotic women from study CR9108963, between 6 and 12 months following cessation of ronacaleret therapy.
- Trial name
- NCT00891553
- Testing
- DXA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 171 people
- Sponsor
- GlaxoSmithKline
Osteoporosis
Transition From Alendronate to Romosozumab (AMG 785)
The purpose of this study is to estimate the percent change from baseline in lumbar spine bone mineral density (BMD) following multiple-dose administrations of romosozumab in postmenopausal women with low BMD previously treated…
- Trial name
- NCT01588509
- Testing
- Romosozumab
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Amgen
Change in Bone Mineral Density, Bone Loss
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in…
- Trial name
- NCT05303636
- Testing
- drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
- Where
- 37 sites in United States, Czechia and 1 more
- Volunteers
- 1,536 people, healthy volunteers welcome
- Sponsor
- Insud Pharma
Osteoporosis
Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD
The main purpose of this study is to assess whether a locally-administered rhBMP-2/CPM injection can rapidly increase bone mass in subjects at high risk for osteoporotic fractures of the hip.
- Trial name
- NCT00752557
- Testing
- rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy), bisphosphonates, calcium, and vitamin D
- Where
- 35 sites in United States, Belgium and 2 more
- Volunteers
- 50 people
- Sponsor
- Pfizer
Joint Disease
Evaluation of Bone Mineral Density Changes After Total Hip Replacement: A Two-Year Clinical and DXA Analysis
Sponsor is conducting this post-market study to evaluate the clinical outcome and femoral bone mineral density (BMD) changes associated with the PROFEMUR® PRESERVE hip stem when used as indicated for primary total hip…
- Trial name
- NCT02865447
- Testing
- total hip arthroplasty implant
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- MicroPort Orthopedics Inc.